Page 15 - linda_borst
P. 15

REFERENCES

                1   Boon, T. & van der Bruggen, P. Human tumor antigens recognized by T lymphocytes. J Exp Med
                    183, 725-729, doi:10.1084/jem.183.3.725 (1996).
                2   Rosenberg, S. A. A new era for cancer immunotherapy based on the genes that encode cancer
                    antigens. Immunity 10, 281-287, doi:10.1016/s1074-7613(00)80028-x (1999).
                3   Old, L. J. Cancer vaccines 2003: opening address. Cancer Immun 3 Suppl 2, 1 (2003).
                4   Scanlan, M. J., Gure, A. O., Jungbluth, A. A., Old, L. J. & Chen, Y. T. Cancer/testis antigens: an
                    expanding family of targets for cancer immunotherapy. Immunol Rev 188, 22-32, doi:10.1034/
                    j.1600-065x.2002.18803.x (2002).
                5   Ilyas, S. & Yang, J. C. Landscape of Tumor Antigens in T Cell Immunotherapy. J Immunol 195, 5117-  Chapter 1
                    5122, doi:10.4049/jimmunol.1501657 (2015).
                6   Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, Adaptive, and Acquired Resistance
                    to Cancer Immunotherapy. Cell 168, 707-723, doi:10.1016/j.cell.2017.01.017 (2017).
                7   Coley, W. B. The Treatment of Sarcoma with the Mixed Toxins of Erysipelas and Bacillus Prodigiosus.
                    The  Boston  Medical  and  Surgical  Journal  158,  175-182,  doi:10.1056/nejm190802061580601
                    (1908).
                8   Coley,  W.  B.  The  Treatment  of  Inoperable  Sarcoma  by  Bacterial  Toxins  (the  Mixed  Toxins
                    of  the  Streptococcus  erysipelas  and  the  Bacillus  prodigiosus).  Proc  R  Soc  Med  3,  1-48,
                    doi:10.1177/003591571000301601 (1910).
                9   Ehrlich, P. & Dale, S. H. H. The Collected Papers of Paul Ehrlich. Vol. II (Pergamon Press, 2013).
                10  Ehrlich, P. Ueber den jetzigen Stand der Karzinomforschung.  (1908).
                11  Burnet,  M.  Cancer;  a  biological  approach.  I.  The  processes  of  control.  Br  Med  J  1,  779-786,
                    doi:10.1136/bmj.1.5022.779 (1957).
                12  Thomas, L. & Lawrence, H. Cellular and humoral aspects of the hypersensitive states. New York:
                    Hoeber-Harper, 529-532 (1959).
                13  Hanahan,  D.  &  Weinberg,  R.  A.  The  hallmarks  of  cancer.  Cell  100,  57-70,  doi:10.1016/s0092-
                    8674(00)81683-9 (2000).
                14  Hanahan,  D.  &  Weinberg,  R.  A.  Hallmarks  of  cancer:  the  next  generation.  Cell  144,  646-674,
                    doi:10.1016/j.cell.2011.02.013 (2011).
                15  Dunn,  G.  P.,  Bruce,  A.  T.,  Ikeda,  H.,  Old,  L.  J.  &  Schreiber,  R.  D.  Cancer  immunoediting:  from
                    immunosurveillance to tumor escape. Nat Immunol 3, 991-998, doi:10.1038/ni1102-991 (2002).
                16  Dunn, G. P., Old, L. J. & Schreiber, R. D. The immunobiology of cancer immunosurveillance and
                    immunoediting. Immunity 21, 137-148, doi:10.1016/j.immuni.2004.07.017 (2004).
                17  Pettit, S. J., Seymour, K., O’Flaherty, E. & Kirby, J. A. Immune selection in neoplasia: towards a
                    microevolutionary  model  of  cancer  development.  Br  J  Cancer  82,  1900-1906,  doi:10.1054/
                    bjoc.2000.1206 (2000).
                18  Smyth,  M.  J.  et  al.  Perforin-mediated  cytotoxicity  is  critical  for  surveillance  of  spontaneous
                    lymphoma. J Exp Med 192, 755-760, doi:10.1084/jem.192.5.755 (2000).
                19  Shankaran, V. et al. IFNgamma and lymphocytes prevent primary tumour development and shape
                    tumour immunogenicity. Nature 410, 1107-1111, doi:10.1038/35074122 (2001).
                20  Koebel, C. M. et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature
                    450, 903-907, doi:10.1038/nature06309 (2007).
                21  Seliger, B., Maeurer, M. J. & Ferrone, S. Antigen-processing machinery breakdown and tumor
                    growth. Immunol Today 21, 455-464, doi:10.1016/s0167-5699(00)01692-3 (2000).






                 GENERAL INTRODUCTION                                                   13
   10   11   12   13   14   15   16   17   18   19   20